• Ziarco Pharma header page image one
  • Ziarco Pharma header page image two
  • Ziarco Pharma header page image three

Our Focus

Inflammatory Skin Diseases

Chronic inflammatory skin disorders such as atopic dermatitis and psoriasis are very common conditions, yet many patients are poorly treated with existing therapies.


Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is a chronic skin disease characterised by inflammation and itch. These symptoms result in a severely reduced quality of life. AD affects 2-3% of adults (males and females equally) and up to 25% of children. AD is often associated with other atopic and inflammatory disorders, such as asthma and allergic rhinitis.


Today, there are no oral safe and effective treatments for chronic use in moderate to severe AD. Current treatments include topical steroids, topical calcineurin inhibitors, oral and topical immunosuppressive agents.



Psoriasis is a chronic, inflammatory skin disease that primarily affects adults. The disease most commonly manifests on the skin of the elbows, knees and scalp, although it can appear on any location, with varying severity.

It is estimated that in the US and Europe, psoriasis affects 2 to 4% of the population. Plaque psoriasis accounts for approximately 90% of the psoriasis population. The most severe psoriasis patients (10-20% of patients depending on country) are typically treated with systemic biological therapies, which are quite effective. However, current treatments for the remaining 80-90% of patients, who are not eligible for treatment with biological therapies, are suboptimal, both in terms of efficacy and safety.

Disease Severity

Disease severityjpg.jpg

Current treatments for both AD and psoriasis are associated with concerns with either poor efficacy and/or potential side effects. This poses a significant healthcare challenge in treating the majority of patients not eligible for treatment with the current or emerging biological therapies in psoriasis and shortly in atopic dermatitis.  These patients have chronic symptoms all year round and the need for new safe and effective treatments is clear. ZPL-389 and ZPL-521 have the potential to provide treatments options that would offer relief to a wide range of patients.